TABLE 1.
Baseline characteristics of dataset 1 (ADNI) and dataset 2.
| Dataset 1 (ADNI 3) | AD (n = 25) | aMCI (n = 42) | CU (n = 24) |
| Demographics | |||
| Age | 73.4 (9.0) | 73.2 (7.3) | 72.3 (5.6) |
| Sex, Fa (%) | 9 (36.0) | 20 (47.6) | 17 (70.8) |
| Education | 15.9 (2.4) | 16.1 (2.5) | 17.0 (1.9) |
| ApoE ϵ4 (%) | 19 (76.0) | 30 (71.4) | 14 (58.3) |
| TIV | 1.57 (0.21) | 1.54 (0.16) | 1.51 (0.12) |
| Pathologic burden | |||
| Tau deposition (SUVR)b | 1.30 (0.38) | 1.12 (0.20) | 1.08 (0.15) |
| Aß deposition (SUVR)c | 1.45 (0.20) | 1.38 (0.19) | 1.21 (0.18) |
| Cortical thickness (mm)c | 2.37 (0.11) | 2.48 (0.08) | 2.51 (0.11) |
| CSF p-tau (pg/ml) | 34.5 (12.7) | 36.1 (19.9) | 26.9 (12.9) |
| CSF t-tau (pg/ml) | 343.6 (104.3) | 341.0 (150.4) | 277.7 (97.7) |
| Cognitive function | |||
| MMSEc | 22.0 (3.2) | 27.3 (2.3) | 29.1 (1.4) |
| Composite (z-scores)c | −3.67 (3.02) | 0.99 (2.25) | 2.92 (1.65) |
| ADNI-MEM (z-scores)c | −0.90 (0.52) | 0.14 (0.55) | 1.02 (0.50) |
| ADNI-EF (z-scores)c | −1.03 (1.15) | 0.34 (0.89) | 0.91 (0.73) |
| ADNI-LAN (z-scores)c | −0.67 (0.92) | 0.40 (0.86) | 0.81 (0.62) |
| ADNI-VS (z-scores)c | −1.12 (1.12) | 0.13 (0.65) | 0.19 (0.71) |
| ADAS-cog 11 (baseline)c | 21.1 (6.7) | 10.2 (4.3) | 5.0 (2.6) |
| ADAS-cog 11 (follow-up)c | 29.5 (11.3) | 13.2 (7.0) | 5.5 (2.4) |
| Dataset 2 | AD (n = 21) | aMCI (n = 32) | CU (n = 34) |
| Demographics | |||
| Agea | 63.2 (11.3) | 69.2 (7.2) | 68.7 (6.8) |
| Sex, F (%) | 14 (66.7) | 23 (71.9) | 22 (64.7) |
| Education | 11.6 (4.4) | 11.0 (4.3) | 10.6 (4.8) |
| ApoE ϵ4b (%) | 9 (42.9) | 17 (53.1) | 6 (17.6) |
| TIV | 1.35 (0.12) | 1.33 (0.13) | 1.37 (0.13) |
| CDR-SBc | 6.39 (3.98) | 1.90 (0.96) | 0.31 (0.43) |
| Pathologic burden | |||
| Tau deposition (SUVR)c | 1.39 (0.09) | 1.32 (0.11) | 1.20 (0.10) |
| Aß deposition (SUVR)c | 1.44 (0.15) | 1.50 (0.14) | 1.10 (0.07) |
| Cortical thickness (mm)c | 2.29 (0.13) | 2.39 (0.11) | 2.45 (0.12) |
| Cognitive function | |||
| MMSEc | 19.4 (5.0) | 24.3 (3.6) | 28.6 (1.2) |
| Compositec | 31.5 (11.1) | 42.8 (9.5) | 61.0 (7.1) |
| Memoryc | 46.1 (13.3) | 61.6 (14.6) | 107.9 (15.2) |
| Executivec | 56.0 (29.8) | 75.5 (24.9) | 102.3 (17.5) |
| Languagec | 34.1 (13.8) | 37.6 (13.4) | 50.8 (5.4) |
| Attentionb | 8.6 (2.3) | 9.3 (2.6) | 11.1 (2.8) |
| Visuospatialc | 12.8 (11.9) | 30.2 (6.2) | 33.0 (4.5) |
| Clinical progression | |||
| Follow-up (month) | 25.8 (12.3) | 29.1 (9.0) | 23.3 (9.1) |
| Conversion to AD, n (%) | – | 17 (53.1) | 1 (2.9) |
| Conversion to aMCI, n (%) | – | – | 1 (2.9) |
Values are mean (standard deviation) or number (%). ap < 0.05; bp < 0.01; cp < 0.001, significant between groups. AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; CU, cognitively unimpaired; ApoE ϵ4, apolipoprotein ϵ4 allele; TIV, total intracranial volume; SUVR, standardized uptake value ratio; p-tau, phosphorylated tau; t-tau, total tau; MMSE, Mini-Mental State Examination; ADAS-cog 11, Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11; Composite score, the average score of five domains; CDR-SB, Clinical Dementia Rating Scale-Sum of Boxes.